Diabetes Intervention Program for Adolescents With Persistent High HA1c

Overview

The purpose of this project is to assess the feasibility and efficacy of a new group therapy program for adolescents with Type 1 diabetes and compromised metabolic control (high A1c). This intervention is aimed at addressing issues frequently found to be associated with poor control: knowledge deficits, parental supervision, parent-teen communication and psychosocial barriers. In order to test this new group therapy program, adolescents' HA1c and psychosocial functioning will be monitored pre- and post-intervention. It is hypothesized that individuals who participate in the group therapy program will show an improvement in their HA1c levels and quality of life, self-efficacy, supportive behaviors from family members, readiness to make improvements in their diabetes care and decrease symptoms of depression.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2015

Detailed Description

Basic Design: This study will pilot a group therapy intervention for adolescents seen in the diabetes clinic who have had elevated HA1c's for at least 3 months. This group will be offered in fall of 2014. Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies. Participants will complete questionnaires measuring self-efficacy, family support, quality of life, readiness to change and symptoms of depression. Questionnaires will be administered at an initial assessment prior to participation in the group, at completion of the 8 week program, at a follow-up visit 2 months following the completion of the group and 1 year post-intervention. Questionnaires will take approximately 45 minutes to complete. HA1c levels will be evaluated for participants every 3 months as per regular clinic care. This intervention program will be offered to teens upon an elevated HA1c result. Primary Outcomes: HA1c levels will be tested every three months as per regular clinic care. Basic demographic information will be obtained from participants during the initial assessment for the group (age, family size, and date of diagnosis of diabetes). Secondary Outcomes: Psychosocial functioning will be evaluated pre- and post-intervention by having participants and their parents fill out the following questionnaires: Self-efficacy for Diabetes Scale (SED); Diabetes Quality of Life for Youths; Diabetes Family Behavior Scale; Beck Depression Inventory for Youth (BDI-Y); Diabetes Management Questionnaire; Child Behavior Checklist (Parent form); Low Blood Sugar Survey, and Children's Hope Scale.

Interventions

  • Behavioral: motivational interviewing group
    • Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.

Arms, Groups and Cohorts

  • Experimental: motivational interviewing group
    • Motivational Group Intervention: Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.

Clinical Trial Outcome Measures

Primary Measures

  • Change from Baseline HA1c at 6 months post baseline
    • Time Frame: Baseline, 6-months post baseline
  • Change from baseline HA1c at 3 months post baseline
    • Time Frame: Baseline, 3-months post baseline
  • Change from Baseline HA1c at 9 months post baseline
    • Time Frame: Baseline, 9-months post baseline
  • Change in Baseline HA1c at 12 months post baseline
    • Time Frame: Baseline, 12-months post baseline

Secondary Measures

  • Change from baseline in Self-efficacy for Diabetes scale (SED) at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Self-efficacy for Diabetes scale (SED) at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Self-efficacy for Diabetes scale (SED) at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Diabetes Family Behavior Scale at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Diabetes Family Behavior Scale at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Diabetes Family Behavior Scale at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Beck Depression Inventory for Youth (BDI-Y) at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Diabetes Quality of LIfe for Youth at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Diabetes Quality of LIfe for Youth at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Diabetes Quality of LIfe for Youth at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Diabetes Management Questionnaire at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Diabetes Management Questionnaire at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Diabetes Management Questionnaire at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Child Behavior Checklist (Parent form) at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Child Behavior Checklist (Parent form) at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Child Behavior Checklist (Parent form) at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Low Blood Sugar Survey at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Low Blood Sugar Survey at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Low Blood Sugar Survey at 60 weeks
    • Time Frame: baseline, 60 weeks
  • Change from baseline in Children’s Hope Scale at 8 weeks
    • Time Frame: baseline, 8 weeks
  • Change from baseline in Children’s Hope Scale at 16 weeks
    • Time Frame: baseline, 16 weeks
  • Change from baseline in Children’s Hope Scale at 60 weeks
    • Time Frame: baseline, 60 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • The therapy group will be composed of teens that currently have a documented history of elevated HA1c's that have persisted for at least 3 months – Potential candidates for the group will be recruited from all the physician's caseloads in the clinic. Exclusion Criteria:

  • Patients with Type II diabetes – Those who are medically unstable due to other medical conditions – Those who refuse to participate will not be included in the study

Gender Eligibility: All

Minimum Age: 13 Years

Maximum Age: 17 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Manitoba
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Heather MacKenzie, Ph.D., C. Psych. Candidate – University of Manitoba
  • Overall Official(s)
    • Heather MacKenzie, PhD, Principal Investigator, University of Manitoba
  • Overall Contact(s)
    • Heather K MacKenzie, PhD, 204-787-8963, hmackenzie3@hsc.mb.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.